Death of TB Champion, Rep. Donald Payne

5 Mar 2012
by Working Group

U.S. Representative Donald Payne (D-NJ)

Statement from RESULTS:

RESULTS Mourns the Death of Rep. Donald Payne

Joanne Carter, Executive Director of RESULTS/RESULTS Educational Fund, issued the following statement:

RESULTS is saddened to learn of the death of Representative Donald Payne, who was a true champion for global health and fighting poverty, particularly in Africa.

As chair and ranking member of the Africa and Global Health Subcommittee, Rep. Payne was an outspoken advocate in the fight against AIDS, tuberculosis, malaria, and other diseases of poverty. His bold leadership was particularly instrumental in increasing funding to combat tuberculosis, the leading killer of people living with HIV/AIDS in sub-Saharan Africa.

Rep. Payne was a steadfast supporter of access to microfinance and education for the very poor, agriculture and nutrition programs to fight hunger, and efforts to bring peace and justice to countries and people in crisis.

We will remember his passionate commitment to these issues. His tireless leadership will be truly missed.

On behalf of RESULTS members in New Jersey and across the country, we extend our sympathies to his family, friends, staff, and colleagues for their loss.

Additional Coverage:

Rep. Donald Payne’s Biography

Donald M. Payne, First Black Elected to Congress From New Jersey, Dies at 77

Rep. Donald Payne of New Jersey dies at age 77 (FOX)

Congressman Donald M. Payne Dead at 77 (Patch)

More News
17 Sep 2019
Earlier this month, the NIH announced two new Funding Opportunity Annoucnements (FOAs) on the topic of Myeloid-Derived Suppressor Cells (MDSC) as potential therapeutic targets in TB/HIV co-infected patients. The purpose of these FOAs is to invite applications for support of innovative clinical,...
14 Aug 2019
FDA released the following press release on Wednesday, August 14th: The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis (TB) of the lungs. “The threat of...
27 Jun 2019
-- Globe Newswire reported on June 20th -- Spero Therapeutics, Inc. , a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections and rare diseases, today...